BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7(1): 33-40 [PMID: 26855810 DOI: 10.4292/wjgpt.v7.i1.33]
URL: https://www.wjgnet.com/1948-5182/full/v7/i1/33.htm
Number Citing Articles
1
Sara Lo Menzo, Enrico Biagi, Mariachiara Di Nuzzo, Anastasio Grilli, Carlo Contini. SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 PatientAnnals of Hepatology 2018; 17(4): 661 doi: 10.5604/01.3001.0012.0950
2
Tung Huynh, Johnathan Zhang, Ke-Qin Hu. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase NormalizationJournal of Clinical and Translational Hepatology 2018; 6(3): 1 doi: 10.14218/JCTH.2018.00014
3
Martha Shumway, Anne F. Luetkemeyer, Marion G. Peters, Mallory O. Johnson, Tessa M. Napoles, Elise D. Riley. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferencesAIDS Care 2019; 31(11): 1340 doi: 10.1080/09540121.2019.1587353
4
Sichan He, Ian Lockart, Maryam Alavi, Mark Danta, Behzad Hajarizadeh, Gregory J. Dore. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinomaAlimentary Pharmacology & Therapeutics 2020; 51(1): 34 doi: 10.1111/apt.15598
5
Jessica Taaffe, David Wilson. Mobilising a global response to hepatitis: Lessons learned from the HIV movementGlobal Public Health 2018; 13(4): 473 doi: 10.1080/17441692.2016.1233989
6
Jason Gummow, Makutiro G. Masavuli, Zelalem A. Mekonnen, Yanrui Li, Danushka K. Wijesundara, Ashish C. Shrestha, Ilia Voskoboinik, Eric J. Gowans, Branka Grubor-Bauk. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C VirusVaccines 2020; 8(1): 53 doi: 10.3390/vaccines8010053
7
Melanie Mallory, David Hillyard. Clinical Virology Manual2016; : 351 doi: 10.1128/9781555819156.ch25
8
Nahed A. Makhlouf, Mohamed Farouk, Hanan Mohamed Nafeh, Ahmad Farooq Alsayed Hasanain, Mohamed Ahmed El-Mokhtar, Helal F. Hetta, Mohamed A. Mekky, Mohamed Alboraie, Hussein ELamin, Ahmed Medhat Nasr. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapyEgyptian Liver Journal 2021; 11(1) doi: 10.1186/s43066-021-00080-0
9
Xiuzhu Gao, Mengru Zhan, Liquan Wang, Yanhua Ding, Junqi Niu. <p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>Journal of Hepatocellular Carcinoma 2020; : 347 doi: 10.2147/JHC.S279657
10
Kosuke Matsumoto, Hisamitsu Miyaaki, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma, Kazuhiko Nakao. The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infectionBiomedical Reports 2021; 16(2) doi: 10.3892/br.2021.1492
11
Elia Moreno-Cubero, Juan-Ram&oacute;n Larrubia. Specific CD8<sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitisWorld Journal of Gastroenterology 2016; 22(28): 6469-6483 doi: 10.3748/wjg.v22.i28.6469
12
Ozge Cevik, Dan Li, Erdene Baljinnyam, Dinesh Manvar, Erica M. Pimenta, Gulam Waris, Betsy J. Barnes, Neerja Kaushik-Basu. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinomaJournal of Biological Chemistry 2017; 292(52): 21676 doi: 10.1074/jbc.M117.792721
13
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo, Yuri Sanchez Gonzalez. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceInfectious Diseases and Therapy 2016; 5(4): 491 doi: 10.1007/s40121-016-0134-x
14
Dalia Morales-Arraez, Manuel Hernandez-Guerra, Felicitas Diaz-Flores, Yolanda Nieto-Bujalance, Jose Garcia-Dopico, Alejandro Jimenez, Enrique Quintero. Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon eraJournal of Public Health 2021; 43(2): 385 doi: 10.1093/pubmed/fdz149
15
Tsung-Lung Tsai, Huei-Min Jhou, Frank S Fan. Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case ReportCureus 2022;  doi: 10.7759/cureus.24193
16
Sandra J. Page, Maria M. Rivera, David E. Kleiner, Xiongce Zhao, Sungyoung Auh, Elaine F. Remmers, Theo Heller. Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCV-related liver damageHepatology Communications 2017; 1(9): 973 doi: 10.1002/hep4.1103
17
Natalia Echeverría, Pilar Moreno, Juan Cristina. Human Virology in Latin America2017; : 333 doi: 10.1007/978-3-319-54567-7_17